EVOK Stock Summary and Trading Ideas (Evoke Pharma | NASDAQ:EVOK)

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma trades on the NASDAQ stock market under the symbol EVOK.

As of March 4, 2025, EVOK stock price climbed to $3.96 with 11,282 million shares trading.

EVOK has a beta of 1.49, meaning it tends to be more sensitive to market movements. EVOK has a correlation of 0.07 to the broad based SPY ETF.

EVOK has a market cap of $5.88 million. This is considered a Sub-Micro Cap stock.

Last quarter Evoke Pharma reported $3 million in Revenue and -$.94 earnings per share. This fell short of revenue expectation by $-706,000 and missed earnings estimates by -$.56.

In the last 3 years, EVOK traded as high as $201.60 and as low as $3.44.

The top ETF exchange traded funds that EVOK belongs to (by Net Assets): VXF.

EVOK has underperformed the market in the last year with a price return of -49.2% while the SPY ETF gained +13.9%. EVOK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.9% and -26.3%, respectively, while the SPY returned -4.2% and -5.4%, respectively.

EVOK support price is $3.34 and resistance is $3.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVOK shares will trade within this expected range on the day.